Functional Consequences of Cognitive Impairment in Parkinson's
PD patients, however, have a specific profile of cognitive and motor impairments that differs from Alzheimer’s. As a result, a methodology specific to PD is needed to accurately classify cognitive features and to assess the impact of potential interventions.
The purpose of this project is to address one aspect of this gap by developing a new clinical measurement tool, the “Functional Consequences of Cognitive Impairment” (FCCI) scale. The study and development of this scale has three aims:
- To conduct qualitative studies to define specifically the functional consequences of cognitive impairment in PD
- To conduct detailed psychometric evaluations of the new FCCI
- To assess the validity of the FCCI in a longitudinal cohort study of PD patients.
This study will produce a reliable measure of the impact of cognitive impairments in basic and instrumental daily functioning in PD and PDD patients. This instrument will also be valuable in clinical trials of cognitive interventions designed to treat or prevent PD.
This study is being conducted at the Penn Neurological Institute at Pennsylvania Hospital, 330 South 9th Street. Participation in the study involves yearly detailed evaluations including motor exams, cognitive testing, and the collection of biological samples. If you have further questions concerning participation, or are interested in participating in this study, please contact:
Katia Duey, Research Coordinator
|Gene Peir, Research Coordinator||Phone: 215-829-7104|
Additional Parkinson’s ongoing studies at Penn
There are additional Parkinson’s and movement disorder studies ongoing at Pennsylvania Hospital. For a listing of these studies with contact information, please visit http://www.uphs.upenn.edu/neuro/research/trials/parkinsons/index.html.